SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings, signaling continued investor appetite for clinical-stage biotechs following the J.P. Morgan conference. Both companies aim to access public capital to advance pipelines and extend clinical programs. Separately, the Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute across Europe, broadening seed and pre-seed support for life‑science startups. Together these moves indicate parallel momentum on public exits and private philanthropic funding that could accelerate early-stage company formation and scale-up across the European biotech ecosystem.